Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
A new Fed letter argues that higher unauthorized immigration during the Biden era helped expand the labor pool in key...
In Buffett's final chapters as Berkshire's CEO, one move stood out: selling a stock that helped build his fortune. Th...
DraftKings chief executive clarifies that bets tied to wars or deaths won’t be offered, even as the company pivots to...
A February pullback gave investors a clearer path to big AI winners. Here are three mega-cap picks, plus concrete ste...
As labor markets stay tight, businesses are learning that unlocking discretionary effort hinges on culture and frontl...
December 2025 is turning market expectations on their head. This update dives into unexpected seller strategies, shif...
As inflation lingers and wages stall, a growing share of Americans are turning down weddings, dinners, and gatherings...
Tesla is betting big on AI by investing in xAI. This article explains what that move could mean for investors, how to...
Global fertilizer supply disruptions push prices higher, threatening farm budgets and consumer costs in the United St...
As gas prices trend higher, Costco’s fuel discounts and bulk-buying model could attract more shoppers. This practical...
Apple launched the MacBook Neo at a budget price, signaling a potential breakthrough for Mac demand. This article bre...